Laboratorio di Immunologia, Istituto di Endocrinologia e Oncologia Sperimentale, Consiglio Nazionale delle Ricerche, Napoli, Italy.
J Reprod Immunol. 2010 Jun;85(2):172-9. doi: 10.1016/j.jri.2010.02.009. Epub 2010 May 7.
This study investigated the in vitro immune-modulating activities of recombinant versus highly purified urinary follicle-stimulating hormone (FSH), luteinizing hormone (LH), and human chorionic gonadotropin (hCG) at the cellular level. CD4(+) T cells were isolated from peripheral blood mononuclear cells obtained from ten healthy women (aged 19-30 years) with regular menstrual cycles during the follicular phase of their cycle. CD4(+) T cells were stimulated with anti-CD3/CD28 monoclonal antibodies as a T cell-specific mitogen. Proliferative and cytokine responses were analyzed at standard time points (72h). Recombinant FSH (r-FSH) and LH (r-LH) alone showed a modest capacity to influence proliferation and cytokine release by CD4(+) T cells. Conversely, their addition to T cells in combination with recombinant hCG (r-hCG) induced a powerful down-modulation of T cell proliferation, decreased interferon-gamma (IFN-gamma) secretion and increased interleukin-10 (IL-10) production. These immune-modulating activities were not present when CD4(+) T cells were stimulated either in the presence of urinary-purified FSH (u-FSH) or human menopausal gonadotropin (HMG), alone or in combination with recombinant hCG. We are the first to suggest that urinary-purified gonadotropins do not display profound immune-modulating activities as compared with the recombinant preparations, despite their endocrine effects. Therefore, the use of the recombinant preparations in assisted reproductive techniques might be relevant not only for their well-documented endocrine actions but also for their impact on the transient immune tolerance known to favour embryo implantation and progression of pregnancy.
本研究在细胞水平上研究了重组与高度纯化的尿促卵泡激素(FSH)、促黄体生成激素(LH)和人绒毛膜促性腺激素(hCG)的体外免疫调节活性。从十个健康女性(年龄 19-30 岁)的外周血单核细胞中分离出 CD4+T 细胞,这些女性在其周期的卵泡期期间具有规律的月经周期。CD4+T 细胞用抗 CD3/CD28 单克隆抗体作为 T 细胞特异性有丝分裂原进行刺激。在标准时间点(72 小时)分析增殖和细胞因子反应。重组 FSH(r-FSH)和 LH(r-LH)单独显示出对 CD4+T 细胞增殖和细胞因子释放产生适度影响的能力。相反,当将它们与重组 hCG(r-hCG)一起添加到 T 细胞中时,诱导 T 细胞增殖的强大下调、干扰素-γ(IFN-γ)分泌减少和白细胞介素-10(IL-10)产生增加。当 CD4+T 细胞在单独存在或与重组 hCG 一起存在的情况下,刺激尿纯化 FSH(u-FSH)或人绝经期促性腺激素(HMG)时,这些免疫调节活性不存在。我们是第一个提出尿纯化促性腺激素与重组制剂相比没有显著免疫调节活性的人,尽管它们具有内分泌作用。因此,在辅助生殖技术中使用重组制剂不仅与其明确的内分泌作用相关,而且与已知有利于胚胎着床和妊娠进展的短暂免疫耐受的影响相关。